Key Developments: Rosetta Genomics Ltd (ROSG.PH)
3.93USD
23 May 2013
$-0.13 (-3.20%)
$4.06
$4.00
$4.00
$3.93
500
--
--
--
Latest Key Developments (Source: Significant Developments)
Rosetta Genomics Ltd Receives Two Key U.S. Patent Allowances
Rosetta Genomics Ltd announced that the Company has received two notices of allowance from the U.S. Patent and Trademark Office (USPTO) for Patent Applications 12/661,041 and 12/850,091. The allowed claims of 12/661,041, entitled microRNAs and Uses Thereof, cover the composition of matter for miR-29c, as well as sequence variants (90% identical thereto), a vector and a probe comprising the same. miR-29c is a core element in the Company's lead commercial product, miRview mets2 diagnostic assay for the identification of the tumor of origin in Cancer of Unknown and Uncertain Primary (CUP). The allowed claims of 12/850,091, entitled Viral and Viral Associated MiRNAs and Uses Thereof, cover the composition of matter for herpes simplex virus 1 miR-H3, miR-H4 and miR-H5, as well as sequence variants (80% identical thereto), a vector and a complementary sequence comprising the same. Full Article
Rosetta Genomics Ltd Announces Exercise and Closing of Underwriters Over-Allotment Option
Rosetta Genomics Ltd announced the sale of an additional 825,000 ordinary shares pursuant to the exercise by the underwriter of the over-allotment option granted to the underwriter in connection with Rosetta's recent public offering of 5.5 million ordinary shares at a price to the public of $5.00 per share. The gross proceeds to Rosetta from the offering, including the exercise of the over-allotment option, were approximately $31.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by Rosetta. Aegis Capital Corp. acted as the sole book-running manager for the offering. Full Article
Rosetta Genomics Ltd. Announces Closing Of Public Offering Of 5.5 Million Ordinary Shares
Rosetta Genomics Ltd. announced the closing of an underwritten public offering of 5,500,000 ordinary shares at an offering price of $5.00 per share. The gross proceeds to Rosetta were $27.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Rosetta. In addition, Rosetta has granted the underwriter a 45-day option to purchase up to 825,000 additional ordinary shares to cover over-allotments, if any. Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of future indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development. Aegis Capital Corp. acted as the sole book-running manager for the offering. Full Article
Rosetta Genomics Ltd. Announces Pricing of Public Offering Of 5.5 Million Ordinary Shares
Rosetta Genomics Ltd. announced the pricing of an underwritten public offering of 5,500,000 ordinary shares at a public offering price of $5.00 per share. The gross proceeds to Rosetta from this offering are expected to be approximately $27.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Rosetta. The offering is expected to close on or about August 8, 2012. In addition, Rosetta has granted the underwriter a 45-day option to purchase up to 825,000 additional ordinary shares to cover over-allotments, if any. Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of future indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development. Aegis Capital Corp. is acting as the sole book-running manager for the offering. A registration statement on Form F-1 relating to the shares was filed with the Securities and Exchange Commission (the SEC) and was declared effective on August 2, 2012. Full Article
Rosetta Genomics Ltd. Secures New York State Department of Health's Approval For miRview lung
Rosetta Genomics Ltd. announced that the New York State Department of Health (NYSDOH) has given the Company conditional approval for its miRview lung assay for testing on patient samples from the State. New York is the only U.S. state that requires an independent regulatory review process for laboratory-developed tests. With this approval, Rosetta Genomics can offer miRview lung in all 50 U.S. states. In making the assay available pending final approval, the NYSDOH requires the Company to provide any additional information they request within 60 business days. miRview lung is the Company's microRNA-based assay that accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. Full Article
Rosetta Genomics Ltd. To Raise $6.6 Million In Registered Direct Offering
Rosetta Genomics Ltd. announced it has entered into definitive agreements with investors to purchase an aggregate of 570,755 ordinary shares at a price of $11.50 per share in a registered direct offering. The offering is expected to close on or about May 31, 2012. Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of existing indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development. Aegis Capital Corp. acted as the exclusive placement agent for the offering. Full Article
Rosetta Genomics Ltd. To Raise $2.2 Million In Registered Direct Offering
Rosetta Genomics Ltd. announced it has entered into definitive agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share in a registered direct offering. The offering is expected to close on or about May 22, 2012, subject to the satisfaction of customary closing conditions. Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of existing indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development. Aegis Capital Corp. acted as the exclusive placement agent for the offering. A shelf registration statement relating to the securities offered and sold in the offering has been filed with the Securities and Exchange Commission (the SEC) and has been declared effective. Full Article
Rosetta Genomics Ltd. Receives U.S. Patent Allowance
Rosetta Genomics Ltd. announced receipt of a patent allowance from the U.S. Patent and Trademark Office (USPTO) for Patent Application 12/800,556 titled, MICRORNAS AND USES THEREOF. Once issued, this patent will provide protection through May 2024. Full Article
Rosetta Genomics Ltd. To Raise $1.38 Million In Registered Direct Offering
Rosetta Genomics Ltd. announced that it has entered into definitive agreements with investors to purchase an aggregate of 8,100,000 ordinary shares at a price of $0.17 per share in a registered direct offering. The offering is expected to close on or about April 17, 2012. Rosetta plans to use the net proceeds from the offering primarily to fund operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of existing indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development. Aegis Capital Corp. acted as the exclusive placement agent for the offering. Full Article
Rosetta Genomics Ltd. Announces $1.75 Million Debt Financing
Rosetta Genomics Ltd. announced that it has sold an aggregate of $1.75 million in senior secured debentures in a private placement transaction with an accredited investor, and Rosetta has also agreed to negotiate in faith a definitive license agreement with a designee of the holders of the debentures for an additional $1.25 million. The debentures have a maturity date of January 26, 2013 and accrue interest at a rate of 10% per annum, payable semi-annually. An aggregate of $300,000 in principal amount of the debentures may be converted into Rosetta's ordinary shares at a conversion price of $0.0944 per share. The debentures are secured by a security interest in all current and future assets of Rosetta and any current or future subsidiary. Full Article
BRIEF-Rosetta Genomics up in premarket after tumor study data
NEW YORK, Jan 9 - Rosetta Genomics Ltd : * Up 19 percent to $5.48 in premarket after tumor study data
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
